Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hetrombopag in Refractory Severe Aplastic Anemia
NCT03557099Phase 2Completed
- Sponsor
- Hengrui
- Start
- Jun 2018
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of hetrombopag in aplastic anemia, sponsored by Hengrui. Primary endpoint: Proportion of Subjects With Hematological Response at 18 weeks. Started Jun 2018; status: completed.
02
Drugs
hetrombopag
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on NCT03557099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03557099.